Menu

ISTOCK, BLACKJACK3D

Support for histone code?

Four papers released online today detail some of the work from David Allis's group and others on chromatin remodeling. 

May 22, 2006
Brendan Maher

Four papers released online today detail some of the work from David Allis's group and others that's detailed in our recent article on chromatin remodeling. In two Nature papers released today, Allis, a Rockefeller chromatin researcher, along with postdocs Joanna Wysocka and Tomek Swigut and a team led by structural biologist Dinshaw Patel, from Memorial Sloan Kettering, report on BPTF, the largest subunit of the nucleosome remodeling factor (NURF). It contains a so-called PHD finger which they've now shown preferentially binds histone 3 trimethylated at lysine 4. They found the protein in pull-down assays and it appears to maintain activity at developmentally critical HOX genes. 

This work is notable for adding support to the controversial histone code hypothesis. The structural work reveals an alpha helix between the PHD finger and a bromodomain. Bromodomain motifs are well known to recognize acetylated lysines, so that unstructured alpha helix might be acting as a spacer between the two recognition motifs. The authors write "The extent to which paired PHD finger-bromodomain in BPTF recognizes combinatorialy methyl and acetyl marks in one or multiple tails, in keeping with the histone code hypothesis remains to be determined." 

I saw Allis give a very engaging talk at Thomas Jefferson University last Thursday, and he was hinting that the "multiple tails" option was looking pretty good. But just in case the relationship between PHD fingers and gene activity sounded straightforward enough, the two other Nature papers released at the same time (and presumably being published in the same print issue) complicate issues, revealing that the PHD domain of tumor suppressor ING2 also recognizes trimethylated H3K4. This is puzzling because ING2 is closely associated with the mSin3a-HDAC1 histone deacetylase, a complex that represses gene transcription. 

Or Gozani at Stanford, Tatiana Kutateladze at University of Colorado Health Science Center and their respective collaborating groups published two papers describing the function and structure of ING2 and its ability to block gene transcription after DNA damage. This is the first protein to link H3K4 methylation to transcriptional repression, and it does it through the same recognition motif (the PHD finger) that Allis's papers describe. They write, "Together, our findings highlight the notion that the recognition of chromatin modifications by effector proteins rather than specific modification per se, determines biological function, and, as such, greatly expands the diversity of signaling at chromatin." 

Allis told me he thought it was fascinating that the same mark (H3K4 trimethylated) might signal both expression and repression. Some researchers argue that if the same signal gives different, even opposite readouts , then there can't be a predictive system. But the context of other signals around H3K4 methylation may play a role in this and other situations.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.